Shares of CVS Health plunged 10.4% to $81.88 on November 4, defying a broad market rally and erasing gains from a speculative run-up tied to the company's announcement that it will split into two publicly traded companies by 2028. The sell-off came despite a quarter that beat Wall Street expectations on both revenue and earnings, raising a sharp question: is the market pricing in execution risk that management hasn't addressed? CVS Beats on Every Line, Announces Historic Breakup — So Why Are Investors Running for the Exit?
Shares of CVS Health cratered 10.4% to $81.88 on November 4, even as the broader market rallied — a jarring disconnect that underscores how deeply Wall Street doubts the company can execute a corporate split while a key insurance business is losing ground.
The Breakup: Unwinding a Two-Decade Bet. CVS plans to separate its roughly 9,000 retail pharmacies from its insurance arm, Aetna, and its pharmacy benefit manager, Caremark, into two publicly traded companies by early 2028.
The move reverses a strategy dating to 2007, when CVS merged with Caremark, and the blockbuster $69 billion Aetna acquisition in 2018.
The split comes amid growing regulatory scrutiny of healthcare companies that control multiple parts of the supply chain. CEO David Joyner is framing this as an offensive move, but investors smell a defensive one — a hedge against political pressure before Congress forces the issue.
A Blowout Quarter the Market Ignored. Adjusted EPS of $2.09 beat the Street's $1.65 estimate by 26.6%, while revenue of $108.4 billion topped consensus by 4.1%.
Management raised full-year adjusted EPS guidance to at least $8.20 and lifted its cash-flow target to at least $15.5 billion from $11.5 billion.
Aetna's medical benefit ratio — the share of premiums spent on patient care — improved to 91.3% from 92.8%, a sign of better cost discipline. Yet the stock sold off, suggesting the breakup announcement created a "sell the news" moment after shares had already climbed roughly 70% under Joyner.
A $2 Billion Medicare Cloud. Aetna's share of Medicare Advantage members in plans rated four stars or above dropped from 84% in 2026 to 67% in 2027. Those ratings determine billions in government bonus payments. CVS is now suing the federal government to recalculate the scores, claiming flawed methodology cost it over $2 billion in 2028 payments.
TD Cowen estimates a $0.41 per-share earnings hit — roughly 4% of the 2028 consensus — which could cut implied 2028 EPS growth from 14% to 9%. For a company asking investors to be patient through a complex separation, that is an uncomfortable headwind.
What Happens Next. CVS must simultaneously run a $420-billion-revenue enterprise, separate two deeply intertwined businesses, and fight a federal lawsuit — all while Aetna's competitive position in Medicare Advantage, the fastest-growing segment of U.S. health insurance, is weakening. Both post-split companies are expected to hold investment-grade credit ratings and pay dividends , but until the market sees a credible bridge from today's conglomerate discount to tomorrow's standalone value, this stock is likely stuck proving itself quarter by quarter.